Linezolid-associated thrombocytopenia in children with severe infection: a retrospective analysis

doi:10.19803/j.1672-8629.2022.08.18

Abstract

Abstract: Objective To investigate the effect of linezolid (LZD) on platelets of children with severe infections. Methods The clinical data on patients hospitalized in the Department of Pediatric Intensive Care Unit (PICU) due to severe infections and treated with linezolid between October 1, 2018 and July 31, 2019 was retrospectively analyzed. Results The median age of the 24 patients enrolled in this study was 5.01 (interquartile range, IQR, 1.75~9.07) years old, six of whom developed linezolid-associated thrombocytopenia (LAT) (2 children received symptomatic treatment with platelet transfusion, and 4 children returned to normal spontaneously) and the incidence of LAT was 25.0%. The median time to onset of LAT and median time to resolution of thrombocytopenia from onset were 4 (IQR, 3.25~5.50) days and 5 (IQR, 3.25~6.75) days, respectively. Conclusion Risk factors for linezolid-associated thrombocytopenia among children with severe infections include low baseline platelet count, high Cmin of linezolid and impairment of visceral function. It is suggested that the dose of LZD should be adjusted individually according to its serum concentration.

Key words: linezolid, pediatric intensive care unit, thrombocytopenia, adverse drug reactions

CLC Number:

R994.11

WANG Yajie, WANG Xiaoling, QIAN Suyun, YANG Mei. Linezolid-associated thrombocytopenia in children with severe infection: a retrospective analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 904-907.

References

[1] DOU LJ, HAN XY, DONG HY.Research progress of linezolid-induced thrombocytopenia[J]. Chinese Journal of Infectionand Chemotherapy(中国感染与化疗杂志), 2019, 19(1): 96-100.
[2] Chief Editor of the Revision Working Group of guiding Principles for Clinical Application of Antimicrobial agents. Guidelines for clinical Application of Antimicrobial Agents[M]. Beijing: People’s Medical Publishing House(抗菌药物临床应用指导原则), 2015.
[3] BAYRAM N, DÜZGÖL M, KARA A, et al. Linezolid-related adverse effects in clinical practice in children[J]. Archivos Argention-sdePediatria, 2017, 115(5): 470-475.
[4] LIN DF, ZHANG YY, WU JF, et al.Linezolid for the treatment of infections caused by Gram-positive pathogens in China[J]. International Journal of Antimicrobial Agents, 2008, 32(3): 241-249.
[5] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clinical Pharmacology＆Therapeutics, 1981, 30(2): 239-245.
[6] Chinese Society of Clinical Oncology. Expert consensus on diagnosis and treatment of chemotherapy-induced thrombocytopenia in cancer patients (2014 Version)[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2014, 36(11): 876-879.
[7] OGAMI C, TSUJI Y, TO H, et al.Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients[J]. Journal of Infection and Chemotherapy, 2019, 25(12): 979-986.
[8] RABON AD, FISHER JP, MACVANE SH, et al.Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater[J]. Annals of Pharmacotherapy, 2018, 52(11) : 1162-1164.
[9] MA JF, LIU YM, ZHANG JT, et al.Retrospective analysis of linezolid-induced thrombocytopenia in elderly patients[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2014, 14(1): 40-43.
[10] HANAI Y, MATSUO K, OGAWA M, et al.A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia[J]. Journal of Infection and Chemotherapy, 2016, 22(8): 536-542.
[11] SIMON A, MÜLLENBORN E, PRELOG M, et al. Use of linezolid in neonatal and pediatric inpatient facilities: results of a retrospective multicenter survey[J]. European Journal of Clinical Microbiology＆Infectious Diseases, 2012, 31(7): 1435-1442.
[12] BAI H, SUN P, CHEN KJ.Meta-analysis of risk factors of linezolid-induced thrombocytopenia[J]. China Pharmacy(中国药房), 2019, 30(7): 121-125.
[13] JONES SJ, NICHOLS KR, DEYOUNG HL, et al.Linezolid-associated thrombocytopenia in children with renal impairment[J]. Journal of the Pediatric Infectious Diseases Society, 2015, 4(3): 272-275.
[14] MORATA L, DE LA CALLE C, GÓMEZ-CERQUERA JM, et al. Risk factors associated with high linezolid trough plasma concentrations[J]. Expert Opinion on Pharmacotherapy, 2016, 17(9): 1183-1187.
[15] KIM HS, LEE E, CHO YJ, et al.Linezolid-induced thrombo-cytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study[J]. Journal of Clinical Pharmacy and Therapeutics, 2019, 44(1): 84-90.
[16] YUAN SN, ZHAO JJ, HAN XY, et al.Influence of bacterial and fungal infections on platelets[J]. Chinese Journal of Nosocomiology(中华医院感染学杂志), 2016, 26(22): 5083-5086.
[17] LI J, FAN YH, LIAO LW, et al.Risk factors for linezolid-associated thrombocytopenia in critically ill adult patients[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2016, 36(9): 743-747.
[18] ZHANG Z, LIANG Z, LI H, et al.Comparative evaluation of thrombocytopenia in adult patients receiving linezolid or glycopeptides in a respiratory intensive care unit[J]. Experimental and Therapeutic Medicine, 2014, 7(2): 501-507.